# Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke

> **NCT07483281** · NA · NOT_YET_RECRUITING · sponsor: **China-Japan Union Hospital** · enrollment: 220 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Human Urinary Kallidinogenase
- **OTHER:** Clinical Routine Treatment

## Key facts

- **NCT ID:** NCT07483281
- **Lead sponsor:** China-Japan Union Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-06-18
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483281, "Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07483281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*